John Mon, COO, of Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) called into SmallCapVoice.com, Inc. to go over the business model, markets, management and much more.
Medifocus develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”). With the recent acquisition of Prolieve®, Medifocus now owns a revenue generating commercial BPH treatment product targeting the estimated $8 billion BPH drug therapy market and generating cash flow to support the development and commercialization of other catheter based or Adaptive Phased Array (APA) based focused heat systems for targeted thermotherapy of surface, subsurface and deep seated localized and regional cancers.
The Company owns two technology platforms with comprehensive US and international patent protection: 1: The Endo-thermotherapy Platform — from which Prolieve was developed can potentially be used to treat cancers in prostate, rectal, cervical and esophageal, and 2: The Adaptive Phased Array (APA) Microwave Focusing Platform — invented by MIT, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company’s APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, is currently in pivotal Phase-III clinical trials.
Please visit www.medifocusinc.com, www.prolieve.com, and http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.